The industry plans to raise an estimated ₹12,000-13,000 crore over the next six to nine months. According to data compiled by The Economic Times, around 15 companies from this sector are likely to enter the primary market soon.
### Market Activity: SEBI Receives DRHPs for Several Companies
The Securities and Exchange Board of India (SEBI) has received draft red herring prospectuses (DRHPs) for Indira IVF and Sahajanand Medical Technologies. Indira IVF refiled in July with an issue size of about ₹3,500 crore, while Sahajanand Medical Technologies filed for a ₹1,500 crore issue.
Other notable filings include:
– NephroPlus (about ₹2,000 crore)
– Molbio Diagnostics (₹200 crore)
– Cotec Healthcare (₹500 crore)
### Fundraising Plans: Companies That Have Received SEBI’s Nod
Several companies have already received SEBI’s approval to launch their initial public offerings (IPOs). These include:
– Rubicon Research, looking to raise ₹1,085 crore
– Corona Remedies, aiming to raise ₹800 crore
Additionally, other companies planning IPOs include:
– Paramesu Biotech (₹600 crore)
– Allchem Lifesciences (₹190 crore)
– Paras Healthcare (about ₹900 crore)
– Veeda Clinical Research (about ₹500 crore)
– Gujarat Kidney and Superspeciality Hospital (₹128 crore)
Genetix Biotech is also planning to file for an IPO soon.
### Trends: ART Sector Attracting Investor Interest Due to Strong Fundamentals
Saurav Chaube, a research analyst at Samco Securities, highlighted a strategic shift in the assisted reproductive technology (ART) sector. He noted that growing investor interest is driven by strong market fundamentals such as increasing infertility awareness and favorable demographics.
Chaube added that companies like Indira IVF and Gaudium IVF have filed through the confidential route. This indicates a maturing market where players aim to optimize their public offerings while minimizing early scrutiny and opportunistic litigation.
### Industry Outlook: Pharma and Healthcare Increasingly in Focus Since COVID-19
Samir Bahl, CEO of Anand Rathi Advisors, observed that global markets have been increasingly focusing on pharma and healthcare sectors since the onset of COVID-19. He pointed out that countries like the US and India are ramping up investments in pharma and biotech innovation.
Bahl also mentioned that Indian pharma companies currently command high price-to-earnings ratios, reflecting favorable valuations and strong investor interest in the sector.
—
The upcoming wave of IPOs and heightened investor enthusiasm underscore the growing prominence of the healthcare and pharma sectors in India’s financial markets.
https://www.newsbytesapp.com/news/business/15-pharma-healthcare-firms-to-launch-ipos-in-coming-months/story
